Tagged with Affordability

USA Joshua Salsi, Head of North America, Biocon Biologics explains the company’s evolution into an integrated, global biosimilars company following the 2022 Viatris portfolio reacquisition. He highlights the company’s growing US leadership, expanding pipeline, vertical integration, and focus on patient access. Salsi goes on to stresses that long-term biosimilar growth depends…

USA Our next phase of evolution is moving from pure-play generics to something more complex across branded products, biosimilars, and NCEs Punit Patel, President and CEO, of Zydus Americas, speaks about leading the company’s pivot from a pure-play generics business into complex generics, biosimilars and new chemical entities. Anchored by its…

USA Tom Shea, Founder and CEO of Meitheal Pharmaceuticals, discusses his career across commercial and operational roles in generic injectables and the creation of Meitheal in 2017. He highlights the company’s growth into a top-five US injectable generic player, its expansion into biosimilars, and its commitment to manufacturing investment, supply reliability,…

USA We have spent the past decade building a strong foundation, investing in the market, expanding our capabilities, and assembling an exceptional team The US generics industry remains central to the healthcare system’s efforts to improve affordability, strengthen supply resilience, and expand patient access to medicines. As Cipla enters its second…

USA If price is the only basis for adoption, biosimilars will not survive as a viable industry Tom Newcomer, SVP & Head of US Commercial, Samsung Bioepis, discusses the company’s evolution into a dedicated biosimilars developer with ten FDA approvals and a long-term commitment to improving affordability and access. He highlights…

USA Harshika Sarbajna, SVP Commercial Global at Alvotech, reflects on the evolution of the US biosimilars market and the company’s strategy for scaling access across key therapeutic areas. In this interview, she discusses launch execution, payer dynamics, interchangeability, and the role of partnerships in driving adoption. She also outlines how pricing…

Taiwan The TGPA’s Tiffany Chen brings over three decades of experience at the intersection of pharmaceuticals, public policy, and industry development. In her current role, she leads advocacy efforts to strengthen regulatory and reimbursement frameworks, safeguard sustainable margins, and reinforce supply resilience in Taiwan. At the same time, she also works…

USA John Murphy III, President and CEO of the Association for Accessible Medicines (AAM), argues that 2026 represents a pivotal moment for the United States to reclaim leadership in biosimilars. He outlines how recent FDA reforms could finally unlock competition, lower drug costs, and expand patient access, while warning that outdated…

USA John Murphy, President and CEO of the Association for Accessible Medicines (AAM), outlines a compelling vision for improving access to high-quality, affordable medicines in the US. He stresses that by directing greater focus to the generic and biosimilar market, tackling structural challenges, safeguarding supply chains, and enabling strategic domestic investment,…

Europe European pharma is at a turning point, with rising cost pressures, regulatory shifts, and supply chain vulnerabilities reshaping the industry. As the new president of Medicines for Europe, STADA’s Stephan Eder is now at the forefront of driving the change that Europe needs. In this new role as head of…

USA Ulrich Neumann examines the debate around drug pricing in the US and why it is not going away any time soon.   Come senators, congressmen Please heed the call Don’t stand in the doorway Don’t block up the hall For he that gets hurt Will be he who has stalled”…

Opinion Pharmaceutical innovation is racing ahead of the US health system’s ability to adjust payment models, but innovative concepts are finally emerging. We will have to move beyond siloed thinking to establish them for the sake of getting patients sustainable access to a new wave of transformative cures, argues Ulrich Neumann.…